SCHEMBL15467238

SCHEMBL15467238

C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)CC4C[C@H](OC(=O)CN)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 6/20 0.77
▸ SLC10A1 Q14973 5/20 0.77
▸ SLC10A2 Q12908 4/20 0.77
▸ TSHR P16473 1/20 0.66
▸ RAB9A P51151 1/20 0.66
▸ LMNA P02545 1/20 0.66
▸ BLM P54132 1/20 0.66
▸ NR1H4 Q96RI1 2/20 0.63
▸ ABCC4 O15439 2/20 0.63
▸ ABCB11 O95342 2/20 0.63
▸ PLA2G1B P04054 1/20 0.63
▸ ENPP2 Q13822 1/20 0.63
▸ CA1 P00915 1/20 0.58
▸ CA2 P00918 1/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ CYP3A4 P08684 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ SLCO1B3 Q9NPD5 1/20 0.58
▸ SLCO1B1 Q9Y6L6 1/20 0.58
▸ USP2 O75604 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7998870 0.92 GPBAR1 (0.86) GPBAR1SLC10A1SLC10A2TSHRRAB9A
SCHEMBL23222893 0.92 GPBAR1 (0.86) GPBAR1SLC10A1SLC10A2TSHRRAB9A
SCHEMBL25791272 0.92 GPBAR1 (0.86) GPBAR1SLC10A1SLC10A2TSHRRAB9A
SCHEMBL23222871 0.92 GPBAR1 (0.86) GPBAR1SLC10A1SLC10A2TSHRRAB9A
SCHEMBL15539504 0.91 GPBAR1 (0.84) GPBAR1SLC10A1SLC10A2TSHRRAB9A
Taurocholate Sulfate SCHEMBL28445221 0.90 GPBAR1 (0.81) GPBAR1SLC10A1SLC10A2TSHRRAB9A
Taurocholate Sulfate SCHEMBL31402018 0.90 GPBAR1 (0.81) GPBAR1SLC10A1SLC10A2TSHRRAB9A
SCHEMBL23222857 0.90 SLC10A1 (0.89) GPBAR1SLC10A1SLC10A2TSHRRAB9A
SCHEMBL5570512 0.90 SLC10A1 (0.89) GPBAR1SLC10A1SLC10A2TSHRRAB9A
SCHEMBL10519939 0.89 GPBAR1 (0.71) GPBAR1SLC10A1SLC10A2TSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49949-E1 Reducing risk of contracting clostridium-difficile associated disease THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2024-04-30 — — US disclosed
US-9862744-B2 Reducing risk of contracting clostridium-difficile associated disease THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2018-01-09 — — US disclosed
US-20160009753-A1 Reducing Risk of Contracting Clostridium-Difficile Associated Disease NATIONAL SCIENCE FOUNDATION 2016-01-14 — — US disclosed
US-9079935-B2 Reducing risk of contracting Clostridium-difficile associated disease THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2015-07-14 — — US disclosed
US-20140045808-A1 Reducing Risk of Contracting Clostridium-Difficile Associated Disease of Nevada, Las Vegas (US) 2014-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045808-A1 Reducing Risk of Contracting Clostridium-Difficile Associated Disease SLC10A2, CDC37, SLC10A1 GPBAR1 34/4885SLC10A1 3/4885SLC10A2 1/4885
US-20160009753-A1 Reducing Risk of Contracting Clostridium-Difficile Associated Disease SLC10A2, CDC37, SLC10A1 GPBAR1 34/4885SLC10A1 3/4885SLC10A2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback